- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket | 2 | Benzinga.com | ||
| REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| Sa | Revelation Biosciences Inc expected to post a loss of $2.29 a share - Earnings Preview | 2 | Reuters | ||
| 08.11. | Revelation Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary | 1 | Reuters | ||
| 08.11. | Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 | 180 | Business Wire | SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity... ► Artikel lesen | |
| 08.11. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 08.11. | REVELATION BIOSCIENCES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 21.10. | Revelation Biosciences faces Nasdaq delisting over noncompliance | 2 | Investing.com | ||
| 21.10. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.09. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.09. | REVELATION BIOSCIENCES, INC. - 10-Q/A, Quarterly Report | - | SEC Filings | ||
| 23.09. | REVELATION BIOSCIENCES, INC. - 10-K/A, Annual Report | - | SEC Filings | ||
| 03.09. | Revelation Biosciences files for secondary offering of about 5.1M shares | 1 | Seeking Alpha | ||
| 26.08. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.08. | Pre-market Movers: Staffing 360 Solutions, Mobix Labs, GD Culture, Revelation Biosciences, Guardion Health Sciences | 611 | AFX News | PHILADELPHIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.25 A.M. ET).In the Green Staffing 360 Solutions, Inc. (STAF) is up over... ► Artikel lesen | |
| 21.08. | Revelation Biosciences announces exercise of warrants for $3.8M in gross proceeds | 1 | Seeking Alpha | ||
| 21.08. | Pre-market Movers: Revelation Biosciences, Stronghold Digital Mining, BigBear.ai, Bio-Path, Mynaric | 792 | AFX News | MINNEAPOLIS (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.55 A.M. ET).In the Green Revelation Biosciences, Inc. (REVB) is up over... ► Artikel lesen | |
| 19.08. | Revelation Biosciences faces Nasdaq delisting over equity deficit | 4 | Investing.com | ||
| 19.08. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.08. | Revelation Biosciences stock hits 52-week low at $0.87 | 1 | Investing.com | ||
| 09.08. | Revelation Biosciences reports Q2 results | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TENAX THERAPEUTICS | 2,770 | 0,00 % | Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative... ► Artikel lesen | |
| ARCADIA BIOSCIENCES | 3,820 | +4,37 % | Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2024 Financial Results and Business Highlights | DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results... ► Artikel lesen | |
| TRACON PHARMACEUTICALS | 1,410 | 0,00 % | TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces it Will Wind Down Operations | SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was... ► Artikel lesen | |
| ALZAMEND NEURO | 1,465 | 0,00 % | Alzamend Neuro Regains Compliance with Nasdaq Listing Standards | ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease... ► Artikel lesen | |
| ARIDIS PHARMACEUTICALS | - | - | Aridis Pharmaceuticals, Inc.: Aridis Provides Corporate Update | LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) ("Aridis" or the "Company"), a biopharmaceutical company, today announced a corporate update on recent... ► Artikel lesen | |
| QIAGEN | 40,180 | -0,06 % | Qiagen - Zarte Ansätze von höherer Nachfrage | Qiagen überzeugt im dritten Quartal mit den stärksten Ergebnissen seit Auftaktquartal 2022. Zwei zentrale Entwicklungen lassen auf weiteres Wachstum hoffen und unterstreichen das Potenzial des Labordienstleisters.... ► Artikel lesen | |
| EVOTEC | 8,630 | +0,76 % | Turnaround: Nicht Evotec: 5 Punkte, die aktuell für Gilead Sciences sprechen | © Foto: picture alliance / ZUMAPRESS.com | Igor GolovniovDas Geschäft und die Aktie des kalifornischen Biopharma-Unternehmens Gilead gaben seit 2015 nach. Nun scheint sich eine Trendwende abzuzeichnen.... ► Artikel lesen | |
| BIONTECH | 98,50 | +0,15 % | GOLDMAN SACHS stuft Biontech auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat Biontech von "Neutral" auf "Buy" hochgestuft und das Kursziel von 90 auf 137 US-Dollar angehoben. Analyst Chris Shibutani bezieht... ► Artikel lesen | |
| GUBRA | 88,00 | 0,00 % | AKTIONÄR-Depotwert Gubra: Der Showdown naht | Die Spannung steigt beim dänischen Wirkstoffforscher Gubra von Tag zu Tag. Denn das Unternehmen will noch im November richtungsweisende Phase-1-Studienergebnisse zum großen Hoffnungsträger GUBamy vorlegen.... ► Artikel lesen | |
| DYNE THERAPEUTICS | 30,370 | 0,00 % | Dyne Therapeutics GAAP EPS of -$0.96 misses by $0.25 | ||
| TARSUS PHARMACEUTICALS | 46,650 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements | Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,74 | -0,05 % | Longboard Pharmaceuticals GAAP EPS of -$0.63 | ||
| AVIDITY BIOSCIENCES | 50,000 | 0,00 % | Avidity Biosciences jumps 16%; reaches all-time high | ||
| TANGO THERAPEUTICS | 3,920 | 0,00 % | Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights | BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 37,690 | 0,00 % | Structure Therapeutics reports Q3 results |
Das Unternehmen REVELATION BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,862 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVELATION BIOSCIENCES INC finden Sie auf Wallstreet Online.
